Translate Bio, Inc.
(NASDAQ : TBIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -1.42%74.851.0%$1999.28m
AMGNAmgen, Inc. -2.53%203.201.3%$920.54m
REGNRegeneron Pharmaceuticals, Inc. 0.45%475.122.6%$805.89m
BIIBBiogen, Inc. -0.98%313.031.5%$744.22m
VRTXVertex Pharmaceuticals, Inc. 0.70%233.551.9%$568.26m
MRNAModerna, Inc. -2.71%29.660.0%$547.51m
ILMNIllumina, Inc. -1.26%272.753.5%$472.25m
ALXNAlexion Pharmaceuticals, Inc. 2.05%89.052.0%$284.35m
AAgilent Technologies, Inc. -1.68%71.451.6%$232.72m
EXASEXACT Sciences Corp. -0.34%58.2321.0%$199.97m
INCYIncyte Corp. 0.83%72.772.5%$178.20m
SGENSeattle Genetics, Inc. 0.46%115.836.1%$170.51m
BMRNBioMarin Pharmaceutical, Inc. 2.74%84.754.3%$165.28m
NVAXNovavax, Inc. -1.66%14.06114.7%$131.28m
ALNYAlnylam Pharmaceuticals, Inc. 1.67%110.658.7%$103.04m

Company Profile

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.